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WHAT IS ALREADY KNOWN ABOUT
THIS SUBJECT
￿ Liraglutide is a novel human GLP-1
analogue approved for treatment of type 2
diabetes mellitus.Since there is a high
prevalence of co-morbid hepatic
impairment in this population it is of clinical
importance to establish whether the
pharmacokinetics of liraglutide are affected
by hepatic impairment.
WHAT THIS STUDY ADDS
￿ This study shows that hepatic impairment
does not increase liraglutide exposure.
Rather,total exposure tends to decrease
with increasing degree of hepatic
impairment.
AIMS
To compare the pharmacokinetics (PK) of a single-dose of liraglutide in
subjects with hepatic impairment.
METHODS
This parallel group,open label trial involved four groups of six subjects
with healthy,mild,moderate and severe hepatic impairment,
respectively.Each subject received 0.75 mg of liraglutide (s.c.,thigh),
and blood samples were taken over 72 h for PK assessment.Standard
laboratory and safety data were collected.The primary endpoint was
area under the plasma liraglutide concentration–time curve from time
zero to inﬁnity (AUC(0,•)).
RESULTS
Exposure to liraglutide was not increased by hepatic impairment.On
the contrary,mean AUC(0,•) was highest for healthy subjects and
lowest for subjects with severe hepatic impairment (severe/healthy:
0.56,with 90% CI 0.39,0.81) and equivalence in this parameter across
groups was not demonstrated.Cmax also tended to decrease with
hepatic impairment (severe/healthy:0.71,with 90% CI 0.52,0.97),but
tmax was similar across groups (11.3–13.2 h).There were no serious
adverse events,hypoglycaemic episodes or clinically signiﬁcant
changes in laboratory parameters and liraglutide was considered well
tolerated.
CONCLUSIONS
This study indicated no safety concerns regarding use of liraglutide in
patients with hepatic impairment.Exposure to liraglutide was not
increased by impaired liver function;rather,the results suggest a
decreased exposure with increasing degree of hepatic impairment.
However,data are not conclusive to suggest a dose increase of
liraglutide.Thus,the results indicate that patients with type 2 diabetes
mellitus and hepatic impairment can use standard treatment regimens
of liraglutide.There is,however,currently limited clinical experience
with liraglutide in patients with hepatic impairment.
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The increasing prevalence of type 2 diabetes mellitus rep-
resents one of the major health-economic challenges of
the 21st century [1, 2]. The aetiology of this disease is
complex and involves increased insulin resistance coupled
withprogressivelossofbeta-cellmassandfunction,result-
ing in chronic hyperglycaemia and associated multiple
morbidities [1, 3].There is evidence that nutrient-induced
secretion of the glucose-regulating incretin hormone,
glucagon-like peptide-1 (GLP-1),is impaired in type 2 dia-
betes mellitus [4].
The potential of GLP-1 as a therapy target in type 2
diabetes has gained increasing attention in recent years.
This insulinotropic hormone is released from the L cells in
the intestine in response to meals [5] to stimulate insulin
secretion and decrease glucagon secretion [5, 6]. Both
actions are glucose-dependent. Hence GLP-1 has the
potential to be harnessed as a type 2 diabetes treatment
that lowers blood glucose with a low risk of hypoglycae-
mia.Also GLP-1 decreases gastric emptying rate and appe-
tite [5, 7], properties that are therapeutically desirable
given the association of type 2 diabetes mellitus with
obesity, and the association of obesity with insulin resis-
tance [8,9].Furthermore,GLP-1 promotes beta-cell growth
and rescue in animal models,offering the theoretical pros-
pect of limiting or reversing disease progression [10–14].
Native GLP-1 is, however, rapidly metabolized by
enzymessuchasdipeptidylpeptidase-IV(DPP-IV),givingit
a very short half-life (t1/2 < 2 min) [5, 15] and limiting its
potential to be deployed as a therapeutic agent [10].Ana-
logues or mimetics of GLP-1 with a prolonged activity will
therefore be required in order to exploit successfully the
actions of GLP-1 in the treatment of type 2 diabetes. One
such agent is liraglutide, a human GLP-1 analogue. The
amino acid sequence of liraglutide has very high (97%)
sequence identity to native GLP-1, but the peptide mol-
ecule is linked via a spacer to a 16-carbon fatty acid
residue,which enables reversible binding to albumin [10].
This structural change results in slow release from the
injection site and decreased susceptibility to degradation
by DPP-IV when in the circulation. Liraglutide conse-
quently has a plasma half-life of ~13 h, making it suitable
for once-daily dosing [16].
Clinical trials with liraglutide in patients with type 2
diabetes show many of the predicted therapeutic proper-
ties;blood glucose is lowered,with a low incidence risk of
hypoglycaemia and a concomitant decrease in body
weight [17–21]. Several other studies have shown lira-
glutide to improve beta-cell function in patients with type
2 diabetes [22–25], and its potential to inhibit beta-cell
apoptosis and preserve beta-cell mass has been demon-
strated in both in vitro [26–28] and in animal studies [29,
30].
As noted above,native GLP-1 is rapidly metabolized by
DPP-IV, which is widely expressed and can be found in
multiple tissues and cell types,as well as in the circulation
[5].Clearance of native GLP-1 and its metabolites is largely
mediated via the kidneys [5].The renal ﬁltration and clear-
ance of liraglutide is largely prevented by high binding to
albumin and metabolic stabilization.Thereby liraglutide is
fully metabolized in the body by sequential cleavage of
small peptide fragments and amino acids, which involves
DPP-IV and neutral endopeptidase (NEP),and clearance of
liraglutide is suggested to take place by multiple organ/
tissues (EMEA/379172/2009). A low potential for pharma-
cokinetic (PK) drug interactions related to cytochrome
P450 and protein binding has been demonstrated (EMEA/
379172/2009).Liraglutide is thus comparable with a large
peptide,with no single organ acting as the major route of
elimination [31], and hence hepatic impairment is not
expected to lead to increased exposure.
Furthermore, type 2 diabetes and hepatic disease are
associated, there being a higher frequency of hepatic
impairment in patients with diabetes than in the general
population [32].
At present there are no clinical data on the effect of
impaired hepatic function on the PK of liraglutide. The
present study therefore sought to provide information on
the PK of single dose liraglutide in subjects with varying
levels of hepatic impairment. The safety proﬁles of lira-
glutide were also assessed and compared by degree of
hepatic impairment.
Methods
Design of study
This was a single centre, single dose, parallel group, open
label trial investigating the PK proﬁle of liraglutide in four
groups of six subjects stratiﬁed by hepatic function: one
healthy group with normal function, and the others with
mild, moderate and severe impairment, respectively. The
trial was conducted according to guidelines for trials in
subjects with impaired hepatic function [33,34].
Subjects
Inclusion criteria for subjects in the trial were men or
women aged 18–75 years,with a body mass index (BMI) of
18.5–40.0 kg m
-2.Subjects had either normal hepatic func-
tion or stable hepatic impairment classiﬁed according to
the Child-Pugh scheme [35]: ﬁve parameters are assessed
and 1–3 points given for each one,as indicated in Table 1.
Subjects are then classiﬁed with impairment of grade A
(mildhepaticimpairment,5–6points),B(moderatehepatic
impairment, 7–9 points) or C (severe hepatic impairment,
10–15 points).
Exclusion criteria included liver transplanted subjects
or signs of acute hepatic insufﬁciency, HIV-positive anti-
body status,major cardiac morbidity or hypertension,any
clinically signiﬁcant disease (other than conditions associ-
ated with hepatic impairment) that could interfere with
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creatinine 130 mmol l
-1). Medications that were consid-
ered as possibly able to interfere with the trial results
were not allowed and included some antidiabetic drugs
(tolbutamide, glipizide), H2-receptor antagonist, cardiac
glycosides, cimetidine, digoxin and non-steroidal anti-
inﬂammatory drugs.Furthermore,the use of any medicine
that the investigator considered could interfere with the
trial results was also disallowed.
Allsubjectsgavetheirwrittenconsentpriortoanytrial-
related procedures. The study was conducted in accor-
dance with the Declaration of Helsinki and Good Clinical
Practice. The study protocol and informed consent infor-
mation were approved by the Bioethics Committee of the
Medical Academy in Warsaw,Poland.
Liraglutide administration and sample
collection
Subjects attended the clinic for a screening visit (visit 1) to
assesstheireligibility,andwerescheduledanappointment
for an in-house visit (visit 2) within the next 4 weeks. For
visit 2,subjects were admitted to the hospital for approxi-
mately 84 h (4 days and 3 nights).A single dose of 0.75 mg
liraglutide was administered subcutaneously in the thigh
in the evening on the ﬁrst day (between 21.00–22.00 h),
using a pen injector.
Atotalof20bloodsampleswerecollectedforPKanaly-
sis:at30and15 minpriortodosing,andat2,4,6,8,9,10,11,
12,13,14,15,16,21,24,36,48,60 and 72 h post dosing.The
frequency of these sample times was designed to capture
multiplereadingsaroundtheknowntmaxofliraglutide[16].
For safety, plasma glucose concentration was measured
before breakfast, lunch and dinner and at bedtime
throughout the in-house period and any hypoglycaemic
episodes were recorded. Hepatic blood ﬂow and portal
vein diameter were assessed by ultrasonography. All sub-
jects continued their usual drug treatments during the
in-house period and were served standard meals and bev-
erages.A follow-up visit (visit 3) was scheduled 1–2 weeks
after visit 2 in order to evaluate safety parameters. Vital
signs, standard 12–lead electrocardiogram (ECG), physical
examination and blood and urine sampling for standard
laboratory assessments were performed at all three visits.
Laboratory assessments
The bioanalysis of liraglutide in plasma was performed
using a validated enzyme-linked immunosorbent assay
(ELISA) [16] by Capio Diagnostik a.s., Copenhagen,
Denmark.The assay measures total liraglutide plasma con-
centration and is speciﬁc for intact liraglutide.The repeat-
ability is 2.4–6.5%,the day-to-day variation is 3.7–10%,the
lower limit of quantiﬁcation is 18 pM,and dilution is docu-
mented up to 16-fold while maintaining linearity.
The plasma protein binding (fb) of liraglutide was mea-
sured in vitro on spiked samples (liraglutide concentra-
tions: 1000, 10 000 and 100 000 pmol l
-1) by reiterated
stepwise equilibrium dialysis by Novo Nordisk A/S, Måløv,
Denmark. Unbound fraction of liraglutide (fu) was calcu-
latedas(100 – fb)%.Forthis,anadditionalamountofblood
(approximately 27 ml) was taken from each trial subject
before liraglutide administration.
Plasma glucose was measured for safety reasons when
subjects were at the site using a glucometer. Analysis for
clinical chemistry and haematology were performed by
MDS Pharma Services Central Lab,Hamburg,Germany.
Endpoints and statistical methods
The primary PK endpoint derived from the liraglutide
plasma proﬁles was the area under the concentration–
time curve from time zero (dosing) to inﬁnity (AUC(0,•)),
estimated by standard non-compartment methods.It was
derived as the sum of two areas;the area under the curve
from zero to last valid measurement t (AUC(0,t)) and the
area under the curve from the last valid measurement to
inﬁnity.AUC(0,t)wascalculatedbythetrapezoidalmethod.
The last area was approximated by the area from t to inﬁn-
ity under an exponential curve with the terminal rate (lz).
In addition secondary standard PK endpoints derived
from the individual liraglutide plasma proﬁles included
maximumconcentration(Cmax),timeformaximumconcen-
tration (tmax),total apparent clearance (CL/F),terminal half-
life (t1/2) and apparent volume of distribution (Vz/F).
Safety endpoints were adverse events, laboratory
parameters(haematology,biochemistry(includingalanine
aminotransferase [ALAT] and aspartate aminotransferase
[ASAT], urinalysis and plasma glucose), physical examina-
tion, vital signs and ECG. Diameter of the portal vein and
hepatic blood ﬂow were measured, and the aetiology of
liver disease was registered.
The between-group comparison was performed using
a linear normal analysis of variance (ANOVA) for the log
transformed values of AUC(0,•).The model included ﬁxed
effects of hepatic group and gender, whereas age and
Table 1
Child-Pugh criteria for assessment of impaired liver function
Points scored for observed ﬁndings
12 3
Encephalopathy grade* 0 1 or 2 3 or 4†
Ascites‡ Absent Slight Moderate
Serum bilirubin (mmol l-1) <34.2 34.2–51.3 >51.3
Serum albumin (g l-1) >35 28–35 <28
Prothrombin time (s prolonged) <4 4–6 >6
*Grade 0: normal consciousness, personality, neurological examination, electro-
encephalogram. Grade 1: restless, sleep disturbed, irritable/agitated, tremor,
impaired handwriting, 5 cps waves. Grade 2: lethargic, time-disoriented, inappro-
priate, asterixis, ataxia, slow triphasic waves. Grade 3: somnolent, stuporous,
place-disoriented, hyperactive reﬂexes, rigidity, slower waves. Grade 4: unrousable
coma, no personality/behaviour, decerebrate, slow 2–3 cps delta activity. †Patients
with encephalopathy grade 3 and 4 were excluded from the study. ‡Patients with
advanced ascites were excluded from the study.
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healthy subjects and of subjects with severe hepatic
impairmentweretobedeclaredequivalentwithrespectto
an endpoint if the 90% conﬁdence interval (CI) of the ratio
between hepatic impaired vs. healthy subjects was fully
contained within the interval (0.70, 1.43). This no effect
boundary was chosen instead of the standard range (0.8,
1.25) based on the broad therapeutic range of liraglutide.
Analyses of secondary endpoints were performed as
describedfortheprimaryendpoint.Theanalysisoftmaxwas
performed by non-parametric methods for independent
samples (Hodges-Lehmann estimator).
RegressionanalysisoflogAUCwasperformedinwhich
log(albumin), log(weight), log(portal vein diameter), age
and gender were accounted for. Statistical analyses were
performed using SAS V.8.0,Proc MIXED.
Results
Study groups
A total of 25 subjects were screened, with one subject
withdrawing consent prior to the commencement of any
trial-related activities.Twenty-four subjects were exposed
to trial product and provided PK data,but one of them did
not attend visit 3 (follow-up). The PK and safety popula-
tions both comprised the 24 subjects.
Baselinecharacteristicsbyhepaticgrouparepresented
in Table 2. All of the 24 enrolled subjects (14 male, 10
female) were Caucasians aged 21–61 years. The groups
were well balanced in terms of gender, weight and BMI,
although subjects with moderate and severe hepatic
impairment tended to be older than subjects in the other
two groups.None of the subjects had clinically signiﬁcant
abnormal hepatic blood ﬂow.Five subjects had type 2 dia-
betes mellitus, three in the mildly, one in the moderately
and one in the severely impaired hepatic group.
Liraglutide pharmakokinetics
The liraglutide concentration proﬁles (Figure 1) showed a
higheraverageconcentrationfrom~5–25 hforthehealthy
subjectscomparedwithsubjectswithhepaticimpairment.
Subjects with severe hepatic impairment had the lowest
average concentration during the entire period.Overall,all
groupsdemonstratedacomparableconcentrationvs.time
proﬁle, with liraglutide concentrations approaching zero
approximately 72 h after administration.
The mean values for AUC(0,•) were highest for healthy
subjects and lowest for those with severe hepatic impair-
ment (Table 3).The 90% CI for the ratio of this parameter
between the group of severely impaired hepatic subjects
and the healthy subject group (0.39, 0.81) was not fully
contained in the pre-speciﬁed interval (0.70,1.43;Table 4).
Equivalence for AUC(0,•) was therefore not demonstrated
for this group comparison. This was also the case for the
other hepatically impaired groups, where hepatic impair-
ment was associated with a lower estimated AUC(0,•)
compared with that of healthy subjects (Tables 3 and 4).
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Mean plasma liraglutide concentration–time proﬁle in healthy and
hepatically impaired subjects. healthy; mild; moderate and
severe hepatic impairment
Table 2
Baseline demographics and characteristics
Hepatic impairment group
Healthy Mild Moderate Severe
Male/female (n) 3/3 4/2 3/3 4/2
Age (years) 43.8 (13.5) 44.5 (12.7) 53.2 (6.6) 49.8 (10.4)
Weight (kg) 79.0 (11.9) 75.4 (18.0) 77.5 (21.6) 74.8 (15.5)
BMI (kg m-2) 27.0 (1.7) 27.1 (5.2) 27.9 (5.2) 25.9 (4.4)
Albumin (g dl-1) 38.2 (2.7) 37.2 (2.6) 35.3 (4.3) 27.8 (4.4)
Bilirubin (mmol l-1) 11.67 (3.33) 15.00 (8.72) 40.83 (12.64) 67.00 (24.41)
PTT (s) 0.17 (0.41) 1.17 (1.17) 2.83 (0.75) 4.83 (1.72)
Encephalopathy (n) (None / 1 and 2) 6/0 6/0 3/3
Ascites (n)
Absent/slight/moderate – 6/0/0 4/2/0 2/0/4
Portal vein (mm) 10.3 (0.8) 12.5 (1.0) 13.6 (1.9) 11.8 (0.8)
Data are presented as mean (SD), or as number of patients, denoted (n). BMI, body mass index; PTT, partial thromboplastin time.
A.Flint et al.
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erate and mild hepatic impairment vs. healthy subjects
were found to be equivalent with respect to t1/2 but not for
any other PK endpoints (Cmax,CL/F,Vz/F;Table 4).
Overall,tmax was similar across groups (11.3–13.2 h) and
there was no statistically signiﬁcant difference between
healthy subjects and subjects with hepatic impairment.In
subjects with severe hepatic impairment tmax occurred 1 h
later, but was similar in subjects with moderate impair-
ment and occurred 0.5 h earlier in subjects with mild
impairment compared with healthy subjects.
A multiple regression analysis was performed with the
primary endpoint as the dependent variable and albumin
as an independent variable. In addition the analysis was
adjustedforage,gender,weightanddiameteroftheportal
vein.This analysis showed that albumin concentration had
a statistically signiﬁcant effect on AUC(0,•)( P = 0.041,data
not shown): the higher the albumin concentration, the
higher the estimated AUC.This tendency is also apparent
in Figure 2. However, as albumin concentration declined
with increasing degree of hepatic impairment,and due to
the small size of this trial, it is not possible to state if the
Table 3
Pharmacokinetic characteristics of liraglutide by degree of hepatic impairment
Hepatic impairment group
Healthy Mild Moderate Severe
AUC (0,•) (pmol l-1 h)
Mean (SD) 179 641 (43 154) 149 812 (70 007) 154 615 (47 939) 105 158 (40 843)
Min–Max 114 195–218 365 87 851–273 622 91 623–208 707 54 724–153 211
Cmax (pmol l-1)
Mean (SD) 6 746 (1 534) 6 433 (3 859) 5 593 (1 558) 4 872 (1 637)
Min–Max 4 852–8 978 4 162–14 202 4 003–7 952 2 769–7 506
tmax (h)
Mean (SD) 12.3 (2.3) 11.3 (3.8) 12.7 (2.3) 13.2 (2.9)
Min–Max 9–15 4–14 10–15 8–16
t1/2 (h)
Mean (SD) 11.2 (1.0) 10.7 (1.1) 11.4 (2.2) 9.5 (1.0)
Min–Max 9.9–12.3 9.1–12.0 9.7–15.6 8.1–10.7
CL/F (l h-1)
Mean (SD) 1.18 (0.33) 1.55 (0.59) 1.42 (0.51) 2.21 (0.99)
Min–Max 0.92–1.75 0.73–2.28 0.96–2.18 1.30–3.65
Vz/F (l)
Mean (SD) 18.7 (3.8) 23.5 (7.9) 23.1 (8.2) 30.2 (13.5)
Min–Max 15.6–25.0 11.9–32.3 14.1–33.9 16.8–50.1
AUC(0,•), area under the liraglutide plasma concentration–time curve from time zero to inﬁnity. The measurements were performed up to 72 h after liraglutide dosing. Cmax,
maximum liraglutide plasma concentration. tmax, time to reach maximum liraglutide concentration. t1/2, terminal plasma half-life calculated as t1/2 = ln2/lz. lz, terminal elimination
rate constant, calculated by log-linear regression on the log linear phase of the plasma concentration proﬁle. CL/F, total apparent clearance, estimated as CL/F = dose/AUC. Vz/F,
apparent volume of distribution, estimated as Vz/F = (CL/F)/lz.
Table 4
Between-group comparison of liraglutide pharmacokinetics.Ratios and 90% CI comparing hepatically impaired groups to the healthy subject group
Hepatic impairment group
Mild/healthy Moderate/healthy Severe/healthy
AUC (0,•) 0.77 (0.53, 1.11) 0.87 (0.60, 1.25) 0.56 (0.39, 0.81)
Estimate (90% CI)
Cmax 0.89 (0.65, 1.21) 0.80 (0.59, 1.09) 0.71 (0.52, 0.97)
Estimate (90% CI)
t1/2 (h) 0.95 (0.83, 1.10) 1.01 (0.88, 1.17) 0.85 (0.73, 0.98)
Estimate (90% CI)
CL/F 1.30 (0.90, 1.87) 1.15 (0.80, 1.66) 1.78 (1.23, 2.58)
Estimate (90% CI)
Vz/F 1.23 (0.86, 1.77) 1.17 (0.82, 1.67) 1.51 (1.05, 2.17)
Estimate (90% CI)
AUC(0,•), area under the liraglutide plasma concentration–time curve from time zero to inﬁnity. The measurements were performed up to 72 h after liraglutide dosing. Cmax,
maximum liraglutide plasma concentration. tmax, time to reach maximum liraglutide concentration. t1/2, terminal plasma half-life calculated as t1/2 = ln2/lz. lz, terminal elimination
rate constant, calculated by log-linear regression on the log linear phase of the plasma concentration proﬁle. CL/F, total apparent clearance, estimated as CL/F = dose/AUC. Vz/F,
apparent volume of distribution, estimated as Vz/F = (CL/F)/lz.
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concentrationsortheotheraspectsofhepaticimpairment.
This was illustrated further by a multiple regression analy-
sis where both albumin and hepatic group were included,
and neither the effect of hepatic group (P = 0.53) nor the
effect of albumin (P = 0.54) was statistically signiﬁcant.
The unbound fraction of liraglutide was very low in all
groups, and no clear association between unbound frac-
tion of liraglutide and hepatic group was found. At a
liraglutide concentration of 1000 pmol l
-1, mean (SD)
unbound percentages were (respectively for the healthy
subjects and mild, moderate and severe hepatic groups):
0.53% (0.46),0.59% (0.61),0.68% (0.45) and 0.40% (0.20).At
a liraglutide concentration of 100 000 pmol l
-1,the respec-
tive unbound fractions were: 0.71% (0.56), 0.52% (0.51),
0.48% (0.30) and 0.35% (0.24). Thus, the observed mean
fraction unbound in the group of subjects with severe
hepatic impairment was,in fact,lower than the mean frac-
tion unbound in the healthy group.
Safety and tolerability
No serious adverse events were reported. Three adverse
eventswerereportedinthistrial,twoofwhich,nauseaand
headache, were experienced by two different subjects in
the moderate hepatic impairment group. These events
were considered possibly related to liraglutide administra-
tion, and both subjects recovered within 1 day. The third
adverse event was an episode of acute bronchitis, experi-
enced 9 days post dosing with liraglutide.No hypoglycae-
mic episodes were reported during the trial period. No
clinically signiﬁcant changes were reported for any of the
laboratory parameters investigated, and there were no
trends for changes by hepatic group evident on liraglutide
administration.This was also true for vital signs,the physi-
cal examination and ECG.
Discussion
The present study has provided reassuring results con-
cerning the use of liraglutide in patients with hepatic
impairment,suggestingthatdrugexposuretoliraglutideis
not increased but may rather be somewhat decreased as a
result of impaired liver function.Liraglutide was well toler-
ated and it can, based on PK variables, be concluded that
patients with type 2 diabetes mellitus and concomitant
hepatic impairment are not expected to require dose
adjustment compared with subjects with normal hepatic
function,when treated with liraglutide.Similarly,renal dys-
function is found not to increase exposure of liraglutide
and no dose adjustment is expected in this patient group
with type 2 diabetes,treated with liraglutide [36].
The general concern with hepatic disease is that expo-
sure to a drug that is extensively metabolised in the liver
will be increased, thereby potentially exaggerating the
pharmacodynamic effects and/or side effects. In the case
ofliraglutide,clearancewasnotexpectedtobehepatically
mediated. Its property of reversible albumin binding has
nevertheless been a contributing factor of this investiga-
tion being undertaken since hepatic impairment is often
associated with reduced albumin concentrations.The vast
majority of liraglutide molecules are circulated reversibly
bound to plasma albumin. As it is the free fraction of lira-
glutide that interacts with GLP-1 receptors, it is possible
that the pharmacodynamic effect will be enhanced in the
setting of reduced circulating albumin concentrations.On
the other hand, a decrease in albumin concentration may
result in an increased rate of metabolism of liraglutide by
DPP-IV and NEP.It is also possible that hepatocyte destruc-
tion in liver disease might result in an increased enzyme
outﬂow [37, 38] with a potential impact on liraglutide
metabolism. However, no association was found between
liraglutide exposure and ALAT or ASAT in this study.
In fact, the present study showed that hepatic impair-
ment tended to decrease exposure to liraglutide. Consid-
ering the primary endpoint, the ratio of AUC(0,•)i n
severely hepatically impaired subjects was estimated at
0.56(90%CI0.39,0.81)versusthatofhealthysubjectswith
normal hepatic function, and reduced estimated ratios
were also shown when subjects with moderate and mild
hepatic impairment were compared with the healthy sub-
jects. It is noteworthy that the half-life of liraglutide was
not affected by hepatic impairment,and this suggests that
the differences in the AUC (0,•) of liraglutide might result
primarily from differences in absorption of the drug from
the subcutaneous depot rather than differences in its sub-
sequent metabolism.
A statistically signiﬁcant positive association between
albumin concentration and liraglutide AUC(0,•)w a s
observed (P = 0.041). Albumin concentration in the
group with severe hepatic impairment was lower
than that of healthy subjects (mean 27.8 mmol l
-1,
range 21–33 mmol l
-1 vs. mean 38.2 mmol l
-1, range
34–42 mmol l
-1), but as albumin is part of the Child-Pugh
classiﬁcation of the hepatic impaired subjects it is not pos-
sible, based on a study of this size, to state if the relation-
ship between liraglutide AUC and hepatic impairment is
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other aspects of hepatic impairment. This was conﬁrmed
by further statistical analysis where no signiﬁcant observa-
tion was found when both albumin and hepatic group
were included in the analysis.
A similar methodology was used in the present trial to
one previously reported that was designed to assess the
impactofrenalimpairmentonliraglutidekinetics[36].This
provides an opportunity to compare data across the
healthy control groups. In fact, this comparison suggests
that healthy controls in the present study had a somewhat
lower (~25%) overall and maximal exposure compared
withhealthycontrolsfromtherenalimpairmentstudy.The
reason for this is not altogether clear,but probably relates
to the choice of the thigh (as opposed to the abdomen) as
the injection site in this study compared with the renal
study [36, 39].The tmax (median 12.5 h) was similar to that
reported here.
No safety concerns were raised during the trial.Both of
thereportedadverseeventsconsideredpossiblyrelatedto
liraglutide administration were experienced by subjects in
the moderate hepatic impairment group. These events, a
moderate episode of nausea and one of headache, were
reported 12 and 18 h post dosing, respectively, and
resolved within a day of reporting.They cannot be attrib-
uted to increased exposure to liraglutide as exposure was
not higher in these subjects than in the healthy controls.
No hypoglycaemic events were reported, and the low
number of adverse events reported overall indicated that
liraglutide was well tolerated at the dose given in all
groups.
Inconclusion,theresultsofthisstudyindicatenosafety
concerns regarding the use of liraglutide in patients with
hepatic impairment. Exposure to liraglutide is not
increased by impaired liver function. Rather, the results
suggest a decreased exposure with increasing degree of
hepatic impairment. However, data are not conclusive to
suggest a dose increase of liraglutide in patients with
hepaticimpairmentandthedegreeofhepaticimpairment
did not appear to be associated with increased risk of
adverseevents.Thus,theresultsindicatethatpatientswith
type 2 diabetes mellitus who also suffer from hepatic
impairment can use standard treatment regimens of lira-
glutide.There is,however,currently limited clinical experi-
ence with liraglutide in this patient group.
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